Intermittent move beyond Blincyto

A swath of data at ASH shows that companies have been able to move beyond the 28-day continuous dosing of Amgen Inc.’s first-generation BiTE, Blincyto, to build next-generation antibodies with more convenient, intermittent dosing and a better safety profile.

Companies expect that these advantages, and the modality’s relative lack of logistical baggage, will position the products to compete with CAR T cells as well. ...